Maria Pihlgren

EPFL Innovation Park EPFL
Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients.

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients.

Journal: Clinical pharmacology and therapeutics
Published: October 07, 2025

Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome.

Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome.

Journal: PloS one
Published: May 12, 2025

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Journal: Nature cancer
Published: October 09, 2023

T cell independent antibody responses with class switch and memory using peptides anchored on liposomes.

T cell independent antibody responses with class switch and memory using peptides anchored on liposomes.

Journal: NPJ vaccines
Published: June 05, 2023

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.

Journal: Blood
Published: December 27, 2022

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.

Journal: Science translational medicine
Published: February 16, 2020

Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression.

Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression.

Journal: Scientific reports
Published: July 13, 2018

Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.

Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.

Journal: Journal of Alzheimer's disease : JAD
Published: December 31, 2016

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.

Journal: Scientific reports
Published: May 20, 2016

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

Journal: Cell reports
Published: November 24, 2015

An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.

An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.

Journal: PloS one
Published: November 06, 2015

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Journal: Journal of Alzheimer's disease : JAD
Published: September 28, 2013
Showing 1-12 of 16

Last Updated: 09/26/2026